8-K filing — Cue Biopharma, Inc. (CUE)
Filed: 2026-08-14 AccNo: 0001193125-26-352126 Size: 413 KB Item 2.02: Results of Operations and Financial Condition
Read original at edgarStocks · News reference
Cue Biopharma Q2 EPS $(24.14) Misses $(1.69) Estimate, Sales $7.877M Beat $3.000M Estimate
Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(24.14) per share which missed the analyst consensus estimate of $(1.69) by 1328.4 percent. This is a 794.07 percent decrease over losses of $(2.70) per share
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 14, 2026, 8:27 PM
- Checked
- Aug 14, 2026, 8:27 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Cue Biopharma Files Prospectus For Resale Of 1,505,570 Shares, Including 87,500 Underlying Pre-Funded Warrants, Issued In $50M July Private Placement
https://www.sec.gov/Archives/edgar/data/1645460/000119312526346867/d136967ds3.htm
Read original at benzingaCue Biopharma Appoints James M. Ahlers CFO
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of James M. Ahlers as Chief Financial
Read original at benzinga